media – Page 189 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Merck reports drop in net income for fiscal 2023

Despite declines in sales and EPS, Merck recorded a stable dividend of €2.20 per share for both 2023 and the preceding year. Merck’s EBITDA dropped by 15.6% from €6.504bn in 2022 to €5.489bn in 2023. Credit: Merck KGaA, Darmstadt, Germany and/or its affiliates. Merck KGaA (Merck) has reported a decline in financial performance for the fiscal year 2023, with net income attributable to shareholders falling by 15.1% to €2.82bn ($3.07bn), compared to €3.326bn in the previous year. Earnings per share (EPS) also saw a decrease of 15.2% to €6.49 from €7.65 in 2022. Group net sales experienced a downturn of 5.6% to €20.99bn from €22.23bn in 2022. The company has cited foreign exchange effects, particularly from the US dollar and the Chinese renminbi, as having a negative 4.1% impact on sales. Earnings before interest, taxes, depreciation and amortisation, a key financial indicator for business operations, also dropped by 15.6% from ...
- Source: drugdu
- 158
- March 9, 2024
The roadmap for generative AI in the pharma industry

AI remained one of the main talking points at CTS Europe, as the roadmap for generative AI was mapped out. In 2022, the launch of the generative Artificial Intelligence (AI) platform ChatGPT broke the record for the fastest-growing consumer application in history. Following the rapid adoption of AI technologies, the pharma sector is now exploring the capabilities and challenges of generative AI as it remains one of the key trends in the industry. However, despite the recent progress in the use of AI in real-world situations, we are still in the early stages of the AI roadmap, research director at GlobalData Josep Bori, at the recently concluded Clinical Trial Supply (CTS) Europe 2024 meeting. Generative AI is a technology capable of generating text, images or other data using generative models, often in response to prompts. Explaining how generative AI works, Bori said: “AI is trying to optimise the output to ...
- Source: drugdu
- 95
- March 9, 2024
NHS to ensure people eligible for very high-risk breast screening are referred

Secondary breast cancer is an important risk factor after receiving radiotherapy for Hodgkin lymphoma NHS England has responded to the recent ministerial statement by newly establishing the Very High Risk (VHR) Pathway through the NHS Breast Screening Programme that invites eligible women for annual testing. The NHS is contacting 1,487 women who are at increased risk of breast cancer due to having radiotherapy involving their chest for Hodgkin lymphoma. Hodgkin lymphoma is an uncommon cancer that develops in the lymphatic system. An important risk factor after radiotherapy can include the development of secondary breast cancer, the most common cancer in the UK. Recently, the minister of state for health and secondary care, Andrew Stephenson, said in his statement that NHS England contacted a group of women who were at “very high risk of breast cancer who have been eligible for annual MRI checks, but who may not have been routinely ...
- Source: drugdu
- 158
- March 9, 2024
US researchers develop algorithm test to identify aggressive ovarian cancers

Researchers from Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed an algorithm to identify high-risk precancerous lesions that lead to ovarian high-grade serous carcinoma (HGSC). Published in Clinical Cancer Research, researchers aimed to develop a tool that could detect and stratify serous tubal intraepithelial carcinomas (STICs) based on key genetic alterations and mutations. STICs are lesions that are presumed to be the main precursors of HGSC, the most common form of ovarian cancer in women. Using a technique called Repetitive Element AneupLoidy Sequencing System (RealSeqS), researchers sequenced 150 DNA samples and analysed the level of aneuploidy, missing or extra DNA chromosomes, in STIC versus HGSC and normal-appearing samples. Results showed that STIC samples had more non-random genetic alterations, including whole and partial deletions of chromosome 17 in the tumour suppressor p53 proteins, while normal-appearing samples had low levels of aneuploidy. The team suggests ...
- Source: drugdu
- 91
- March 9, 2024
Simple Blood Test Could Detect Risk of Viral Infection-Induced Cardiac Arrest

Myocarditis, an inflammation of the heart often caused by the body’s immune response to a viral infection, can cause sudden cardiac death. Alarmingly, myocarditis accounts for up to 42% of sudden cardiac deaths in young adults, with viral infection being the primary cause. Traditionally, clinical understanding has focused on how inflammation affects heart rate or rhythm. Now, a new understanding from the latest research suggests completely different directions to diagnose and treat viral infections affecting the heart A new study led by scientists from the Fralin Biomedical Research Institute at Virginia Tech (Blacksburg, VA, USA) has discovered that the virus itself can create dangerous conditions in the heart even before inflammation begins. The study identified an acute phase where the virus first invades the heart, preceding the onset of inflammation due to the body’s immune response. This early infection stage sets the stage for arrhythmias before any tissue inflammation. The ...
- Source: drugdu
- 96
- March 9, 2024
Novel Test Identifies Aggressive Ovarian Cancers Early

Ovarian high-grade serous carcinoma (HGSC) is the predominant form of ovarian cancer affecting women. Serous tubal intraepithelial carcinomas (STICs), which are precancerous lesions on the fallopian tubes, are considered the main precursors of HGSC. Women undergoing salpingectomy, the surgical removal of fallopian tubes, often do so without a detailed examination of these precancerous lesions. The challenge lies in the molecular diversity of STICs and the difficulty in detecting aggressive forms early, owing to their small size. In response to this urgent diagnostic need, researchers have developed an algorithm to identify STICs before they can progress to cancer. This pioneering algorithm, named “REAL-FAST” (RealSeqS-based algorithm for fallopian tube aneuploidy pattern in STIC), was developed by a team at Johns Hopkins Medicine (Baltimore, MD, USA). In a pilot study, REAL-FAST distinguished five unique types of precancerous lesions in fallopian tubes, with two identified as particularly aggressive and often linked to recurrent HGSC. ...
- Source: drugdu
- 127
- March 9, 2024
FDA Approves Opdivo Plus Chemotherapy for Frontline Treatment of Unresectable, Metastatic Urothelial Carcinoma

Davy James Opdivo (nivolumab) plus cisplatin and gemcitabine was found to improve overall survival and progression-free survival compared with chemotherapy alone in patients with unresectable or metastatic urothelial carcinoma.The FDA has approved Bristol Myers Squibb’s Opdivo (nivolumab) plus cisplatin and gemcitabine in the frontline treatment of adults with unresectable or metastatic urothelial carcinoma (UC).1 The regulatory action adds to an array of approved indications for Opdivo, both as a single agent and in combination therapy, including for patients with unresectable or metastatic melanoma; metastatic non-small cell lung cancer; advanced renal cell carcinoma; classical Hodgkin lymphoma; recurrent or metastatic squamous cell carcinoma of the head and neck; locally advanced or metastatic UC; microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer; and hepatocellular carcinoma.2 “This approval marks an important advancement in a historically difficult-to-treat setting, where there has been a need for new and differentiated first-line approaches that may offer patients ...
- Source: drugdu
- 133
- March 9, 2024
Novo Nordisk Obesity Pill Flashes the Potential to Beat Wegovy in Weight Loss

Novo Nordisk reported its weight loss pill amycretin led to greater weight loss measured at 12 weeks compared to clinical trial results for its blockbuster obesity drug Wegovy. But these results are from a small Phase 1 study and more testing is needed. By FRANK VINLUAN An experimental Novo Nordisk obesity pill led to weight loss of 13.1% in a clinical trial, topping results posted in studies of the company’s approved injectable medication Wegovy. It’s early days and more testing is needed, but the preliminary data suggest that this pill has the potential to offer patients superior weight shedding in a more convenient oral formulation. Phase 1 data for the once-daily Novo Nordisk pill, amycretin, were presented Thursday during a company investor event. The study followed participants for 12 weeks. In that span, those who received a placebo lost 1.1% of their body weight. Wegovy, which is administered as a ...
- Source: drugdu
- 185
- March 9, 2024
Where there is a challenge, there is an opportunity

The challenges and opportunities surrounding Africa becoming a clinical trials global force were discussed on day one of CTS Europe. Révérien Uwacu speaking about the five African countries that have a WHO maturity level of three, signifying high capability of overseeing clinical trials. Image credit: Jenna Philpott/GlobalData. Over 18% of the global population lives in Africa, but less than 3% of clinical trials are conducted there. Is there an opportunity for clinical trials to be conducted in Africa? Experts at the ongoing Clinical Trial Supply (CTS) Europe meeting say the answer is yes, but not without its challenges. Leading the session, “Increasing diversity: supply chain considerations for clinical trials in Africa”, Révérien Uwacu, clinical trial supply management consultant for the pharma company UCB, emphasised the importance of diversity in clinical trials, for scientific, moral, and medical reasons. Révérien cited logistical challenges and regulatory complexities in trial supply management, as some ...
- Source: drugdu
- 155
- March 9, 2024
Gilead and Merus enter trispecific antibody discovery deal

The agreement outlines the potential for Merus to earn up to $1.5bn payments from Gilead. Merus will head the early-stage research works for two programmes, with the option to expand to a third asset. Credit: aslysun / Shutterstock.com. Gilead Sciences has entered a research partnership, option and licence agreement with Merus for the discovery of dual tumour-associated antigens targeting trispecific antibodies. The partnership will leverage Merus’ Triclonics technology and Gilead’s capabilities in the oncology field. The aim is to advance multiple preclinical research programmes that could potentially transform cancer treatment. Merus focuses on the development of full-length, multispecific antibodies named Biclonics and Triclonics, referred to collectively as Multiclonics. These antibodies are created by a common light chain technology. The Triclonics trispecific platform creates antibodies that can target three different antigens simultaneously. Merus will spearhead the early-stage research works for two programmes, with the option to expand to a third asset. ...
- Source: drugdu
- 114
- March 9, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.